Aems
Denver, US · Founded 2019 · Delaware corporation
AEMS Corp solves viscosity problems in liquid formulations using proprietary and patented methods and an automated high-throughput, microscale lab, focusing primarily on next-generation pharmaceuticals such as high-concentration injectable biologics and siRNA therapeutics. It also formulates antimicrobial and edible sprayable coatings and other molecular systems for companies whose product development is blocked by viscosity challenges.
Founders & leadership
Aems was founded in 2019 by Nicholas Collella, W. Scott Compel, Alexander R. Hendricks, and Nick Colella.
Board
Reported raises · per SEC filings
Form D private placements$725K disclosed across 4 rounds · 2020–2026
▶$100KraisedMar 2026 · 4 investors · Other TechnologyRule 506(b)
- William S. CompelExecutive Officer, Director
- Michael ChangDirector
- Nick TraggisDirector
- Offering amount
- $700K
- Amount sold
- $100K
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$225KraisedMay 2025 · 4 investors · Other TechnologyRule 506(b)
- Michael ChangDirector
- William CompelExecutive Officer, Director
- Nick TraggisDirector
- Offering amount
- $500K
- Amount sold
- $225K
- First sale
- May 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$250KraisedOct 2023 · 4 investors · Other TechnologyRule 506(b)
- Michael ChangDirector
- Nicholas CollellaDirector
- William CompelExecutive Officer, Director
- Offering amount
- $250K
- Amount sold
- $250K
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$150KraisedAug 2020 · 2 investors · Other TechnologyRule 506(b)
- Nicholas J. ColellaDirector
- William Scott CompelExecutive Officer, Director
- Offering amount
- $200K
- Amount sold
- $150K
- Minimum investment
- $10K
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Aems for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| Centers for Disease Control and Prevention (CDC)Centers for Disease Control and Prevention | Phase I | 2022 | $200K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Aems do?
- AEMS Corp solves viscosity problems in liquid formulations using proprietary and patented methods and an automated high-throughput, microscale lab, focusing primarily on next-generation pharmaceuticals such as high-concentration injectable biologics and siRNA therapeutics. It also formulates antimicrobial and edible sprayable coatings and other molecular systems for companies whose product development is blocked by viscosity challenges.
- Who founded Aems?
- Aems was founded by Nicholas Collella, W. Scott Compel, Alexander R. Hendricks, Nick Colella in 2019.
- How much funding has Aems raised?
- Aems has disclosed $725K raised across 4 rounds.
- Where is Aems headquartered?
- Aems is headquartered in Denver, US.